Psoriatic Arthritis
📧 Sign up to get email alerts when something new happens for Psoriatic Arthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-11-15Clinical Trial Update: A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis [Phase 3]
Phase 3 long-term efficacy and safety study of ixekizumab in active psoriatic arthritis has completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-11-06Clinical Trial Update: Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)
Post-marketing observational study evaluating the impact of AbbVie's Patient Support Program on patient-reported outcomes and health resourc…
-
CLINICAL_TRIALS trial_result · 2019-10-25Clinical Trial Update: Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease [Phase 3]
Phase 3 trial update evaluating a self-injection e-device for certolizumab pegol in several inflammatory diseases; study completed with resu…
-
CLINICAL_TRIALS trial_result · 2019-10-23Clinical Trial Update: Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis [Phase 2]
Phase II study of Apremilast (CC-10004) in adults with psoriatic arthritis completed; results posted.
-
CLINICAL_TRIALS trial_result · 2019-10-21Clinical Trial Update: Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis [Phase 3]
Phase 3 clinical trial comparing tofacitinib to methotrexate for psoriatic arthritis has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-10-08FDA Approved: OLUMIANT — Supplemental Application (Eli Lilly and Company)
FDA approves Eli Lilly's supplemental application for OLUMIANT (baricitinib). This action updates the labeling to reflect expanded indicatio…
-
CLINICAL_TRIALS trial_result · 2019-09-27Clinical Trial Update: Psoriasis-Arthritis & Bone Program [Phase 2]
Phase 2 clinical trial update for a psoriasis-arthritis and bone program completed, investigating treatments for psoriasis and psoriatic art…
-
CLINICAL_TRIALS trial_result · 2019-09-27Clinical Trial Update: Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker [Phase 4]
A Phase 4 clinical trial update evaluating abatacept's effects on bone changes and bone biomarkers in patients with psoriatic arthritis.
-
FDA approval · 2019-09-24FDA Approved: SIMPONI — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for SIMPONI (golimumab) submitted by Janssen Biotech, Inc. The approval updates the drug's label…
-
FDA approval · 2019-08-30FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ (tofacitinib) submitted by Pfizer Laboratories Div Pfizer Inc, marking an approved modif…
-
CLINICAL_TRIALS trial_result · 2019-08-16Clinical Trial Update: Prospective Evaluation of the Radiographic Efficacy of Enbrel
Completed clinical trial investigating radiographic efficacy of Enbrel in rheumatoid arthritis and psoriatic arthritis; results posted in 20…
-
FDA approval · 2019-07-25FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA entry describing a supplemental application for XELJANZ (tofacitinib) submitted by Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2019-07-25FDA Approved: XELJANZ XR — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ XR (tofacitinib extended-release), expanding its formulation under Pfizer's submission.
-
FDA approval · 2019-07-23FDA Approved: HADLIMA — Original Application (Organon LLC)
FDA approves Hadlima (adalimumab-bwwd) from Organon as a biosimilar to Humira under the original application BLA761059. It is indicated for …
-
EMA safety_alert · 2019-07-12PRAC recommends new measures to avoid dosing errors with methotrexate
The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommends new measures to prevent dosing errors with methotrexate, including e…
-
CLINICAL_TRIALS research · 2019-07-05Clinical Trial Update: A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )
A completed registry study evaluating HUMIRA (adalimumab) in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, with res…
-
CLINICAL_TRIALS trial_result · 2019-07-02Clinical Trial Update: 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis [Phase 3]
Phase 3 trial updates show 16-week efficacy and 2-year safety, tolerability, and efficacy data for secukinumab in active psoriatic arthritis…
-
CLINICAL_TRIALS trial_result · 2019-06-28Clinical Trial Update: Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis [Phase 3]
Phase 3 clinical trial update for secukinumab in active psoriatic arthritis evaluating efficacy, structural damage inhibition, safety, and t…
-
CLINICAL_TRIALS trial_result · 2019-06-24Clinical Trial Update: A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.
Clinical trial update assessing the efficacy of etanercept over 12 months in routine treatment of rheumatoid arthritis and related inflammat…
-
CLINICAL_TRIALS trial_result · 2019-06-21Clinical Trial Update: A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta [Phase 1]
Phase 1 postmarketing transfer study evaluating Cimzia (certolizumab pegol) from mother to infant via placenta has completed with results po…
-
FDA approval · 2019-06-13FDA Approved: AMJEVITA — Supplemental Application (Nuvaila Limited)
The FDA approved a supplemental application for AMJEVITA (adalimumab-atto) submitted by Nuvaila Limited.
-
CLINICAL_TRIALS trial_result · 2019-06-12Clinical Trial Update: Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis [Phase 3]
Extension study up to 3 years for secukinumab in psoriatic arthritis completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-05-30Clinical Trial Update: BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis [Phase 2]
Phase 2 trial update comparing BI 655066/ABBV-066 (risankizumab) to placebo in active psoriatic arthritis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-05-28Clinical Trial Update: A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171) [Phase 2]
Phase 2 clinical trial update evaluating safety of risankizumab in psoriatic arthritis patients who completed Week 24 of a prior study.
-
EMA safety_alert · 2019-05-17Restrictions in use of Xeljanz while EMA reviews risk of blood clots in lungs
The EMA announced restrictions on the use of Xeljanz (tofacitinib) while it reviews the risk of blood clots in the lungs, indicating potenti…